Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology (Wittenkeller, et al, 2025)

"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."

"...psychotherapy is essential for the safety and efficacy of psychedelic-assisted therapy... Insight from naturalistic settings emphasizes the importance of group dynamics and context."

"There were no adverse events of special interest, and no unexpected or serious adverse events. The study met the primary objectives of safety and feasibility, and provided indications of efficacy for MDMA-AT for MDD. Further studies with a randomised design are required to confirm these findings."

"This integrative study identifies robust diagnostic biomarkers and nominates ketamine for repurposing in AD. Experimental validation of ketamine's neuroprotective effects and FIBP's role is warranted."

In this phase 2b, multicenter, randomized, double-blind, placebo-controlled study of 4 dose levels of MM120 (a form of LSD) that included 198 adults with generalized anxiety disorder 4 was statistically significant.

"Patients treated with ketamine demonstrated superior cognitive functioning compared with ECT following a 3-week treatment, no differences between treatments observed. Findings support short-term superiority of ketamine on cognitive functioning and the long-term cognitive safety of both treatments."